// App-Quantinova.ai

2466 : Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.

Researchers

Presenter

  • Praveen Kaudlay

Principal Investigators

  • Haiying Hua

  • Guansheng He

  • Darren J Newton

  • Abraham M Varghese

  • Talha Munir

  • Anita Hill

  • Richard J Kelly

  • Stephen John Richards

  • Peter Hillmen

Medical Centers

  • The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom

  • St. James's University Hospital, Leeds, United Kingdom

  • St. James's University Hospital, Leeds, United Kingdom

  • The First Affiliated Hospital of Soochow University Jiangsu Institute of Hematology Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China

  • The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China

Locations

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Age-Related Macular Degeneration

  • Hyperbilirubinemia

  • Aplastic anemia

  • IgA nephropathy

  • Lipodystrophy

  • Renal disease

  • Venous thrombosis

  • Anemia

Biomarkers

  • Cluster of Differentiation 55

  • Cluster of differentiation 59

  • Cluster of differentiation 79A

  • Complement 3

  • Lactate dehydrogenase

  • Red Blood Cells

Drug/Treatment

  • Eculizumab

  • short-acting APL-1

  • APL-2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved